Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Plurinuva is the former name of Ever After Foods, an Israeli cultivated-meat technology company spun out of Pluri and backed by Tnuva Group. The company develops a proprietary bioreactor and cell-expansion platform designed to improve the scalability and cost efficiency of cultivated meat, fish, and seafood production. Rather than operating as a traditional therapeutics developer, it appears to follow a business-to-business model that partners with food and cultivated-protein companies on scale-up validation and pre-commercial deployment. Its technology originated from Pluri’s cell expansion capabilities and has been positioned as a way to reduce capex and opex barriers in cell-based food manufacturing. The company is active, but it is not a life science, biotech therapeutics, pharma, or healthcare company in the conventional analyst sense.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Plurinuva.